

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Merckle GmbH	05/28/2009
RECEIVING PARTY DATA	
Name:	c-a-i-r biosciences GmbH
Street Address:	Paul-Ehrlich-Strasse 15
City:	Tuebingen
State/Country:	GERMANY
Postal Code:	72076
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10367105
CORRESPONDENCE DATA	
Fax Number:	(617)227-4420
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6175175569
Email:	mcarr@eapdlaw.com
Correspondent Name:	Jeffrey D. Hsi
Address Line 1:	PO Box 55874
Address Line 4:	Boston, MASSACHUSETTS 02205
ATTORNEY DOCKET NUMBER:	60633(50551)
NAME OF SUBMITTER:	Jeffrey D. Hsi
Total Attachments: 4 source=60633 assign#page1.tif source=60633 assign#page2.tif source=60633 assign#page3.tif source=60633 assign#page4.tif	

CH \$40.00 10367105

ASSIGNMENT

THIS ASSIGNMENT, made this 28 day of May, 2009,
by Merckle GmbH (hereinafter referred to as Assignors), a corporation organized
under and pursuant to the laws of Germany having its principal place of business at
Graf-Arco-Strasse 3; 89079 Ulm; GERMANY, respectively;

WHEREAS, Assignors have invented certain new and useful improvements
in CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR
THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL
APPLICATIONS THEREOF, set forth in a Patent application for Letters Patent of the
United States, already filed on February 14, 2003 as U.S. Application No. 10/367,105;
and

WHEREAS, c-a-i-r biosciences GmbH, organized under and pursuant to the
laws of GERMANY having its principal place of business at Paul-Ehrlich-Strasse 15,
72076 Tuebingen, GERMANY (hereinafter referred to as Assignee), is desirous of
acquiring the entire right, title and interest in and to said inventions and said
Application for Letters Patent of the United States, and in and to any Letters Patent of
the United States to be obtained therefore and thereon.

NOW, THEREFORE, in consideration of good and sufficient consideration,
the receipt of which is hereby acknowledged, Assignors have sold, assigned,
transferred and set over, and by these presents do sell, assign, transfer and set over,
unto Assignee, its successors, legal representatives and assigns, the entire right, title
and interest in and to the above-mentioned inventions and application for Letters
Patent, and in and to any and all direct and indirect divisions, continuations and
continuations-in-part of said application, and any and all Letters Patent in the United
States and all foreign countries which may be granted therefor and thereon, and
reissues, reexaminations and extensions of said Letters Patent, and all rights under
the International Convention for the Protection of Industrial Property, the same to be
held and enjoyed by Assignee, for its own use and benefit and the use and benefit of
its successors, legal representatives and assigns, to the full end of the term or terms

for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

AND for the same consideration, Assignors hereby represent and warrant to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors are the sole and lawful owners of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignors hereby request the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

AND Assignors hereby grant the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

EDWARDS ANGELL PALMER & DODGE LLP

All practitioners at Customer Number 21874

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made, the effect of this assignment including as of the filing date of the above-identified application(s) and any applications from which the above-identified application(s) claim benefit of.

28 May 2009
Date

ppa K. H. Emmert (a. l. l. u.)
Merckle GmbH
Dr. Karl Heinz Emmert
Member of the Executive
Committee R&D Biotechnologie
Dr. Matthias Eschricht
General Counsel

Witness:

29 May 2009
Date ✓

I. A. Nicola Thiemer
Nicola Thiemer
Secretary R&D Biotechnologie